Help personalize your patients’ cancer treatment

Woman receiving personalized treatment

Across cancer types, universal hereditary cancer genetic testing can help personalize your care approach¹

Genetic testing can help optimize colorectal cancer patient care.

Learn more

Genetic testing informs breast cancer patient care.

Learn more

Over 20% of ovarian cancer patients have an inherited gene variant.1,12,13 Hereditary genetic test results are important for identifying patients who need targeted therapy. Targeted treatments such as PARP inhibitors (sometimes preceded by platinum-based chemotherapy) can improve progression-free survival outcomes in both frontline and recurrent settings.14 The Invitae Multi-Cancer Panel is a cross-cancer test with 13 genes linked to ovarian cancer.

Get actionable insights for prostate cancer.

Learn more

Up to 16% of pancreatic cancer patients have an inherited gene variant.1,18,19 In a 2021 study, the majority (71%) of positive genetic results conferred eligibility for DNA damage repair (DDR) gene-specific precision therapies or clinical treatment trials.20,21 The Invitae Multi-Cancer Panel is a cross-cancer test with 20 genes linked to pancreatic cancer.

Shaping the world of genetic testing

With groundbreaking research 1 and over 1.9 million unique gene variants identified,2 we’re not waiting for the world to catch up; we’re shaping it with you. Universal hereditary cancer genetic testing can help transform care 3,4 for your oncology patients. Unlock their future today for all their tomorrows.

  • Without hereditary cancer genetic testing, a crucial part of their cancer puzzle may be missing

    Patients who harbor hereditary variants could benefit from tailored management, including colorectal (~14%), breast (~12%), ovarian (~21%), prostate (~14%), and pancreatic (~14%) cancer.4

42%

Nearly half of those patients didn’t have a suggestive family history

Testing only patients who meet guidelines criteria may lead to missing up to 42% of patients with an inherited pathogenic variant.1 Genetic testing for all cancer patients helps ensure you don’t miss genetic information that can guide their treatment.1 Invitae’s simple workflow makes ordering tests easy.

Test today for their tomorrow

ASCO=American Society of Clinical Oncology
JAMA=Journal of the American Medical Association

References

1. Samadder NJ, et al. JAMA Oncol. 2021 Feb 1;7(2):230–237.
2. Invitae data on file.
3. Whitworth PW, et al. JAMA Network Open. 2022;5(9).
4. Esplin ED, et al. JCO Precis Oncol. 2022;6:e2100516.
5. Moretz C, et al. JAMA Network Open. 2022;5(10).
6. Naumann RW, et al. Gynecol Oncol. 2018;151(3)477–480.
7. Muller C, et al. JCO Precision Oncology. 2021;(5):1103–1111.
8. Coughlin Sarah E, et al. JCO Precision Oncology 6 (2022): e2200517.
9. What is Genetic Testing? Understanding Genetic Testing for Cancer. Updated September 14, 2022. Accessed May 13, 2023. https://www.cancer.org/cancer/risk-prevention/genetics/genetic-testing-for-cancer-risk/understanding-genetic-testing-for-cancer.html.
10. Beitsch PD, et al. J Clin Oncol. 2018;37(6):453–460.
11. Yang S, et al. Ann Surg Oncol. 2018;25(10):2925–2931.
12. Walsh T, et al. Proc Natl Acad Sci USA. 2011;108(44):18032–18037.
13. Norquist BM, et al. JAMA Oncol. 2016;2(4):482–490.
14. Kurnit KC, et al. Obstet Gynecol. 2021;137(1):108–121.
15. Nicolosi P, et al. JAMA Oncol. 2019;5(4):523–528.
16. Pritchard CC, et al. N Engl J Med. 2016;375(5):443–453.
17. Giri VN, et al. J Clin Oncol. 2020;38(24):2798–2811.
18. Esplin ED, et al. J Clin Oncol. 2020;38(15_suppl):e16783-e16783.
19. Salo-Mullen EE, et al. Cancer. 2015;121(24):4382–4388.
20. Golan T, et al. N Engl J Med. 2019;381(4):317–327.
21. Uson PLS Jr, et al. Clin Transl Gastroenterol. 2021 Oct 8;12(10):e00414.